Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

November 15, 2020

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2014

Registry: Newer P2Y12 Inhibitors Reduce Stent Thrombosis, Mortality Over Clopidogrel

Yael L. Maxwell

November 17, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.